Skip to main content
Erschienen in: AIDS and Behavior 9/2018

05.01.2018 | Original Paper

Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis

verfasst von: Karen Shiu-Yee, Ahnalee M. Brincks, Daniel J. Feaster, Jemima A. Frimpong, Ank Nijhawan, Raul N. Mandler, Robert Schwartz, Carlos del Rio, Lisa R. Metsch

Erschienen in: AIDS and Behavior | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Using baseline data from the NIDA Clinical Trials Network 0049 study (Project HOPE), we performed latent class analyses (LCA) to identify discrete classes, or clusters, of people living with HIV (PLWH) based on their past year substance use behaviors and lifetime arrest history. We also performed multinomial logistic regressions to identify key characteristics associated with class membership. We identified 5 classes of substance users (minimal drug users, cocaine users, substantial cocaine/hazardous alcohol users, problem polysubstance users, substantial cocaine/heroin users) and 3 classes of arrest history (minimal arrests, non-drug arrests, drug-related arrests). While several demographic variables such as age and being Black or Hispanic were associated with class membership for some of the latent classes, participation in substance use treatment was the only covariate that was significantly associated with membership in all classes in both substance use and arrest history LCA models. Our analyses reveal complex patterns of behaviors among substance using PLWH and suggest that HIV intervention strategies may need to take into consideration such nuanced differences to better inform future studies and program implementation.
Literatur
1.
Zurück zum Zitat Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.CrossRefPubMedPubMedCentral Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Palepu A, Tyndall MW, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JSG. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32:522–6.CrossRefPubMed Palepu A, Tyndall MW, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JSG. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32:522–6.CrossRefPubMed
3.
Zurück zum Zitat Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individual in the United States and Canada. PLoS ONE. 2013;8(12):e81355.CrossRefPubMedPubMedCentral Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individual in the United States and Canada. PLoS ONE. 2013;8(12):e81355.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.CrossRefPubMedPubMedCentral Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kipp AM, Rebeiro PF, Shepherd BE, et al. Daily marijuana use is associated with missed clinic appointments among HIV-infected persons engaged in HIV care. AIDS Behav. 2017;[ePub ahead of print]. Kipp AM, Rebeiro PF, Shepherd BE, et al. Daily marijuana use is associated with missed clinic appointments among HIV-infected persons engaged in HIV care. AIDS Behav. 2017;[ePub ahead of print].
6.
Zurück zum Zitat Qian H-Z, Mitchell VJ, Bebawy S, et al. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infect Dis. 2014;14:508.CrossRefPubMedPubMedCentral Qian H-Z, Mitchell VJ, Bebawy S, et al. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infect Dis. 2014;14:508.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.CrossRefPubMedPubMedCentral Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Howe CJ, Cole SR, Napravnik S, et al. The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV+ African Americans. AIDS Res Hum Retrovir. 2014;30(3):233–40.CrossRefPubMed Howe CJ, Cole SR, Napravnik S, et al. The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV+ African Americans. AIDS Res Hum Retrovir. 2014;30(3):233–40.CrossRefPubMed
9.
Zurück zum Zitat Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–20.CrossRefPubMed Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–20.CrossRefPubMed
10.
Zurück zum Zitat Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–9.CrossRefPubMed Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–9.CrossRefPubMed
11.
Zurück zum Zitat Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefPubMed Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefPubMed
12.
Zurück zum Zitat Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.CrossRefPubMed Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.CrossRefPubMed
13.
Zurück zum Zitat Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.CrossRefPubMed Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.CrossRefPubMed
14.
Zurück zum Zitat Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.CrossRefPubMed Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.CrossRefPubMed
15.
Zurück zum Zitat Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep. 2002;117(Suppl 1):S60–6.PubMedPubMedCentral Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep. 2002;117(Suppl 1):S60–6.PubMedPubMedCentral
16.
Zurück zum Zitat Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.CrossRefPubMed Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.CrossRefPubMed
19.
Zurück zum Zitat Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31.CrossRefPubMedPubMedCentral Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Rozanova J, Brown S-E, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice. 2015;3:18.CrossRefPubMedPubMedCentral Rozanova J, Brown S-E, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice. 2015;3:18.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRefPubMedPubMedCentral Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kranofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205. Kranofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205.
23.
Zurück zum Zitat Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2nd ed. 2001. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2nd ed. 2001.
25.
Zurück zum Zitat Derogatis LR, Fitzpatrick M. The SCL-90-R, the brief symptom inventory (BSI), and the BSI-18. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment: instruments for adults, vol 3. 3rd ed. Mahwah: Lawrence Erlbaum Associates Publishers; 2004. p. 1–41. Derogatis LR, Fitzpatrick M. The SCL-90-R, the brief symptom inventory (BSI), and the BSI-18. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment: instruments for adults, vol 3. 3rd ed. Mahwah: Lawrence Erlbaum Associates Publishers; 2004. p. 1–41.
26.
Zurück zum Zitat Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94.CrossRef Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94.CrossRef
27.
Zurück zum Zitat Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535–69.CrossRef Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535–69.CrossRef
28.
Zurück zum Zitat Mplus Version 7.0 [computer program]. Version 7th. Los Angeles, California: Muthén & Muthén; 2012. Mplus Version 7.0 [computer program]. Version 7th. Los Angeles, California: Muthén & Muthén; 2012.
29.
Zurück zum Zitat Stata Statistical Software. Release 12 [computer program]. College Station: StataCorp LP; 2011. Stata Statistical Software. Release 12 [computer program]. College Station: StataCorp LP; 2011.
30.
Zurück zum Zitat Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92(440):1375–86.CrossRef Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92(440):1375–86.CrossRef
31.
Zurück zum Zitat Wang C-P, Hendricks Brown C, Bandeen-Roche K. Residual diagnostics for growth mixture models. J Am Stat Assoc. 2005;100(471):1054–76.CrossRef Wang C-P, Hendricks Brown C, Bandeen-Roche K. Residual diagnostics for growth mixture models. J Am Stat Assoc. 2005;100(471):1054–76.CrossRef
32.
Zurück zum Zitat Rubin DD. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.CrossRef Rubin DD. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.CrossRef
33.
Zurück zum Zitat Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRefPubMedPubMedCentral Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94.CrossRefPubMed Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94.CrossRefPubMed
35.
Zurück zum Zitat Korthuis PT, Fiellin DA, McGinnis KA, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8.CrossRefPubMedPubMedCentral Korthuis PT, Fiellin DA, McGinnis KA, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Reilly KH, Neaigus A, Wendel T, Marshall DM IV, Hagan H. Bisexual behavior among male injection drug users in New York City. AIDS Behav. 2016;20(2):405–16.CrossRefPubMed Reilly KH, Neaigus A, Wendel T, Marshall DM IV, Hagan H. Bisexual behavior among male injection drug users in New York City. AIDS Behav. 2016;20(2):405–16.CrossRefPubMed
38.
Zurück zum Zitat Lurigio AJ. The first 20 years of drug treatment courts: a brief description of their history and impact. Fed Probat. 2008;72(1):13–7. Lurigio AJ. The first 20 years of drug treatment courts: a brief description of their history and impact. Fed Probat. 2008;72(1):13–7.
39.
Zurück zum Zitat Tross S, Campbell AN, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of a NIDA Clinical Trials Network trial. J Acquir Immune Defic Syndr. 2008;48(5):581–9.CrossRefPubMedPubMedCentral Tross S, Campbell AN, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of a NIDA Clinical Trials Network trial. J Acquir Immune Defic Syndr. 2008;48(5):581–9.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Alemi F, Taxman F, Baghi H, Vang J, Thanner M, Doyon V. Costs and benefits of combining probation and substance abuse treatment. J Ment Health Policy Econ. 2006;9(2):57–70.PubMed Alemi F, Taxman F, Baghi H, Vang J, Thanner M, Doyon V. Costs and benefits of combining probation and substance abuse treatment. J Ment Health Policy Econ. 2006;9(2):57–70.PubMed
42.
Zurück zum Zitat Abraham AJ, O’Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder (SUD) treatment programs. J Subst Abuse Treat. 2014;44(1):120–5.CrossRef Abraham AJ, O’Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder (SUD) treatment programs. J Subst Abuse Treat. 2014;44(1):120–5.CrossRef
43.
Zurück zum Zitat Aletaris L, Roman PM. Provision of onsite HIV services in substance use disorder treatment programs: a longitudinal analysis. J Subst Abuse Treat. 2015;57:1–8.CrossRef Aletaris L, Roman PM. Provision of onsite HIV services in substance use disorder treatment programs: a longitudinal analysis. J Subst Abuse Treat. 2015;57:1–8.CrossRef
44.
Zurück zum Zitat Feletcher BW, Lehman WEK, Wexler HK, Melnick G, Taxman FS, Young DW. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend. 2009;103(Supplement 1):S54–64.CrossRef Feletcher BW, Lehman WEK, Wexler HK, Melnick G, Taxman FS, Young DW. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend. 2009;103(Supplement 1):S54–64.CrossRef
Metadaten
Titel
Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis
verfasst von
Karen Shiu-Yee
Ahnalee M. Brincks
Daniel J. Feaster
Jemima A. Frimpong
Ank Nijhawan
Raul N. Mandler
Robert Schwartz
Carlos del Rio
Lisa R. Metsch
Publikationsdatum
05.01.2018
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 9/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-2024-y

Weitere Artikel der Ausgabe 9/2018

AIDS and Behavior 9/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.